StrainX Bioworks Secures Fresh Capital For Expansion
Indian synthetic biology startup StrainX Bioworks has raised $13 million in a fresh funding round co-led by Prime Venture Partners and Leo Capital. The funding round also witnessed participation from Good Startup, Sparrow Capital, Sun Icon Ventures, Dhoka Ventures and WTF (India) Delhi Angels.
The Bengaluru-based startup said the newly raised capital will be used to strengthen research and development capabilities, expand fermentation infrastructure, grow its scientific and engineering workforce and accelerate global commercialisation efforts.
The latest funding reflects increasing investor confidence in India’s growing biotechnology ecosystem, especially in sectors such as synthetic biology and precision fermentation, which are gaining global momentum due to rising demand for sustainable food technologies and alternative protein solutions.
Startup Focuses On Precision Fermentation And Alternative Proteins
Founded in 2023 by Akshay Mittal and Alok Malaviya, StrainX Bioworks develops proprietary enzymes, proteins and metabolites for industries including food, healthcare and agriculture.
The startup operates in the synthetic biology and precision fermentation segment, where engineered microorganisms are used to produce ingredients traditionally sourced from plants or animals. Through biotechnology-driven manufacturing systems, the company aims to create scalable and sustainable alternatives for the global food and nutrition industry.
According to the company, it spent the last two years operating in stealth mode while building capabilities across strain engineering, fermentation, process scale-up and product development. The startup is now preparing for large-scale commercial expansion in both domestic and international markets.
Company Demonstrates Industrial-Scale Fermentation
StrainX Bioworks revealed that it has already demonstrated fermentation at the 10,000-litre scale, marking a major milestone in its journey towards industrial-scale manufacturing.
The company is currently focused on scaling production capacity further as it prepares to commercialise its products across India and overseas markets, including the United States. Its integrated platform combines biotechnology research, fermentation infrastructure, process engineering and product development into a unified system designed to accelerate the transition from laboratory innovation to industrial manufacturing.
Industry experts believe scaling fermentation infrastructure remains one of the biggest barriers for alternative protein startups globally. Companies capable of achieving commercial-scale production efficiently are expected to gain a significant competitive advantage in the rapidly evolving biotechnology industry.
Synthetic Biology Sector Witnesses Rising Global Interest
Synthetic biology is increasingly emerging as a transformative sector within global biotechnology. While the technology has historically been used in pharmaceuticals, companies are now exploring applications across food, agriculture, nutrition and consumer products.
The process involves engineering microbes to produce specific molecules inside controlled fermentation systems. These microorganisms can then manufacture proteins and ingredients at scale with potentially lower environmental impact compared to traditional production systems.
Growing concerns around sustainability, food security and climate change are driving investor interest in alternative protein and biotechnology startups worldwide. As production technologies continue to improve and costs decline, precision fermentation is expected to play a major role in reshaping the future of food manufacturing.
StrainX Plans Global Commercial Expansion
With fresh funding secured, StrainX Bioworks plans to accelerate commercialisation efforts while strengthening partnerships across global markets.
The startup is expected to deepen its focus on sustainable food ingredients, next-generation proteins and industrial biotechnology solutions as demand for climate conscious manufacturing continues to rise. The latest investment also positions StrainX Bioworks among a growing group of Indian deep-tech startups building globally competitive biotechnology platforms from India.
